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Pre-chemotherapeutic factors to assess the prognosis of patients with advanced urothelial carcinoma
have not yet been completely established. The immune response of the host to the tumor is lymphocyte-
dependent. However, the effect of lymphocytes on chemotherapy prognosis is unknown. In this study, we
investigated the correlation between pre-chemotherapeutic lymphocyte counts and the clinical characteristics
of urothelial carcinoma and determined the effectiveness of lymphocytes as a prognostic predictor for
metastatic urothelial carcinoma treated with chemotherapy. Between April 2003 and March 2011, data
from 34 patients with unresectable or metastatic urothelial carcinoma were retrospectively subjected to
multivariate regression analysis to determine the patient characteristics with independent prognostic
significance for survival. The median patient age was 71 ; 21 patients were male and 13 female. The
number of primary tumors in the pelvis, ureter, and bladder were four, six, and 24, respectively. Seventeen
patients underwent prior curative resections, and visceral metastases at chemotherapy were detected in 14
patients. The median lymphocyte count at chemotherapy was 1,292/ml. Cancer-specific survival was
significantly lower in patients with lymphocyte counts ＜1,000/ml than in patients with lymphocyte counts
≥1,000/μ l (p＝0.001). During multivariate analysis, visceral metastasis and lymphocyte counts were
independent factors for predicting poor prognosis. In addition, lymphocyte counts of ＜1, 000/ml or
positive visceral metastases also affected survival. This information may be useful for identifying patients
who are likely to benefit from chemotherapy.
(Hinyokika Kiyo 60 : 215-219, 2014)























法，2008年以降は GC (gemcitabine，cisplatin) 療法を
第一選択とした．プラチナ製剤はシスプラチンを第一
泌尿紀要 60 : 215-219，2014年 215
Table 1. Patient characteristics
Number of cases 34























Table 2. Pre-chemotherapeutic laboratory data
Laboratory data Median Range
LDH (IU/l) 197 131- 425
Albumin (g/dl) 3.6 2.3- 4.4
CRP (mg/dl) 0.8 0.0- 10.6
Hb (g/dl) 12.2 7.3- 14.2
Plt (×104 cells/μl) 25.0 15.7- 46.0
WBC (cells/μl) 6,400 3,800-10,400
Neutrophil (Neu) (cells/μl) 4,172 2,145- 7,613
Lymphocyte (Ly) (cells/μl) 1,292 450- 3,105











ちい，Kaplan-Meier 法で算出し，log-rank test で検定
した．生存率に有意差があったリンパ球数に対して
は，100個/μl ごとにカットオフ値を設定し，Kaplan-















あり，転移部位は肺 7 例，骨 6 例，肝臓 2 例，脳 1
例，卵巣 1例であった．導入時の化学療法は MVAC
療法が 9例，GC 療法が23例，シスプラチン単独が 2
例であった (Table 1）．化学療法施行サイクル数は
1∼11回（中央値 3回）．末梢血リンパ球数の中央値














ン値において p＜0.2 となった．その 3項目を用いて
多変量解析を行ったところ実質臓器転移を有すること
(HR : 3.474，95％ CI : 1.41∼8.57，p-value : 0.007），
末梢血リンパ球数が 1,000個/μ l 未満であること
















Fig. 1. Kaplan-Meier analysis of cancer-specific
survival, (A) primary site of disease, (B)






Fig. 2. Kaplan-Meier analysis of cancer specific
survival, (A) two categories of lymphocyte
counts : ≥1,300/μl and ＜1,300/μl, (B) two
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